A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)

Inclusion Criteria: * Histologically confirmed R/R B-cell malignancy: DLBCL (THRLBCL, EBV-positive DLBCL of the elderly, Grade 3b FL, HGBL with MYC and BCL2 and/or BCL6 rearrangements, transformed lymphoma); MCL ((with cyclin D1 overexpression or t(11;14); FL (Grade 1, 2, 3a); MZL (extranodal, nodal, splenic) ; CLL, or SLL * Willingness to undergo biopsy * At least 2 prior systemic treatment regimens, including prior treatment with an anti-CD20 antibody (all cohorts) or prior treatment with a BTK inhibitor (CLL/SLL) * Relapsed, progressive, or refractory NHL or CLL * For NHL/SLL: Radiographically measurable nodal or extranodal disease (all cohorts except CLL) * ECOG-PS 0 - 2 * LVEF ≥ 50% * Adequate renal, hepatic, bone marrow function Exclusion Criteria: * Any other histological type of lymphoma * Primary or secondary CNS lymphoma * Anticancer and/or investigational therapy within the past 30 days or 5 half-lives * Allogeneic stem cell transplantation within the past 6 months, or ASCT within 3 months before C1D1 * Previous treatment with CD19-targeted therapy or PI3K inhibitors * Clinically significant cardiac disease * Other malignancy within the past 3 years * Active graft-versus-host disease * Stroke or intracranial hemorrhage within the past 6 months * Chronic or current active infectious disease * Positive virus serology for HCV, HBV, HIV * Currently pregnant or breastfeeding